Hot Features
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxy... Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.21 | -14.4827586207 | 1.45 | 1.455 | 1.22 | 944777 | 1.32962425 | CS |
| 4 | -0.66 | -34.7368421053 | 1.9 | 1.97 | 1.22 | 1521770 | 1.55050217 | CS |
| 12 | -0.51 | -29.1428571429 | 1.75 | 2.34 | 1 | 2017608 | 1.64544315 | CS |
| 26 | -1.43 | -53.5580524345 | 2.67 | 3.4 | 1 | 3324505 | 2.02089723 | CS |
| 52 | -0.46 | -27.0588235294 | 1.7 | 3.4 | 1 | 2496862 | 1.99762008 | CS |
| 156 | -2.5 | -66.8449197861 | 3.74 | 4.1 | 0.6254 | 1208225 | 1.8870463 | CS |
| 260 | -4.27 | -77.4954627949 | 5.51 | 9.8465 | 0.6254 | 794385 | 2.2320553 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.